Effects of Iressa with Chemotherapy in Head and Neck Cancer
Author Information
Author(s): Magné N, Fischel J L, Dubreuil A, Formento P, Marcié S, Lagrange J-L, Milano G
Primary Institution: Centre Antoine Lacassagne
Hypothesis
Does the sequence of administering ZD1839 ('Iressa') with radiation and chemotherapy affect the cytotoxic effects in head and neck cancer cell lines?
Conclusion
Applying ZD1839 before radiation and chemotherapy may enhance treatment effectiveness for head and neck cancer.
Supporting Evidence
- High levels of EGFR expression are linked to poor prognosis in head and neck cancer.
- ZD1839 applied before radiation showed the best cytotoxic effects.
- The combination of ZD1839 with cisplatin and/or 5-FU was found to be sequence dependent.
- Cell lines with p53 mutations and high EGFR levels showed the strongest effects.
- Statistical analysis indicated significant differences in treatment effectiveness based on the sequence of drug administration.
Takeaway
This study found that giving a drug called Iressa before radiation and chemotherapy can help fight head and neck cancer better.
Methodology
The study used six head and neck cancer cell lines to assess the cytotoxic effects of ZD1839 combined with radiation and chemotherapy through MTT assays.
Limitations
The study was conducted in vitro, and results may not directly translate to clinical outcomes.
Statistical Information
P-Value
P=0.002
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website